HeartSciences (HSCS)

Traditional ECG devices are widely available, relatively low cost, and routinely used in clinics, emergency rooms, physician offices, and other care locations. However, standard ECG interpretation has limitations, especially when clinicians are screening for structural or ischemic heart disease that may not be obvious from conventional ECG outputs. HeartSciences aims to build on this existing infrastructure by applying algorithms that can extract additional clinical insights from ECG data.

The company is developing a suite of AI-ECG diagnostic solutions that can be used in different healthcare environments. Its MyoVista Insights cloud platform is intended to work with ECG data from devices already in clinical use, potentially allowing providers to enhance current workflows without replacing large amounts of installed equipment. HeartSciences also has the MyoVista wavECG device, which combines ECG acquisition with its proprietary signal analysis approach.

HeartSciences’ broader objective is to make cardiac screening more accessible at the point of care. Earlier identification of heart disease can be important because many cardiovascular conditions progress before symptoms become severe enough to prompt specialist evaluation.

As a listed medical technology company, HSCS is tied to the commercialization of AI-enabled diagnostics, regulatory pathways, clinical adoption, reimbursement dynamics, and competition from established ECG manufacturers and digital health companies. Its investment case depends on whether its technology can demonstrate clinical usefulness and fit efficiently into real-world healthcare practice.